KFDA to exclude new drugs in re-examination from list of items subject to notification

Published: 2004-08-16 06:59:00

Updated: 2004-08-16 06:59:00

The Korea Food and Drug Administration announced on August 11 that new drugs in the process of re-examination will be excluded from the list of notification items whose safety and efficacy has been already established, as part of efforts to facilitate the product application procedures of drug ma...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK